Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​de...
Last updated: 2026-07-09 00:41:15 ET
July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​de...
Why Are Traders Rechecking AstraZeneca And Genus As Healthcare Sentiment Shifts?
/PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical...
Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under ...
AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE